Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Bioanalysis

Overcoming bioanalytical challenges during the development of risdiplam for the treatment of spinal muscular atrophy

View Full Paper
Ask AI
Bookmark
Share

Authors

KHKatja HeinigPDPaweł DżygielLFLuca Ferrari

Discussion

Loading...

Member takes

Overview

Analysis identifies bioanalytical challenges measuring risdiplam in plasma and urine, suggesting improvements for drug development.

Key Points

  • Successful analysis of risdiplam and its metabolite in various samples enhances treatment for spinal muscular atrophy.
  • Key challenges included light sensitivity and nonspecific binding, complicating the drug measurement across species.
  • Bioanalytical methods were adapted to tackle issues such as carryover and the complex analysis of tissue samples.
  • Overcoming these bioanalytical challenges is crucial for ensuring accurate measurements in clinical settings.

Cite This Study

Heinig et al. (2025) studied this question.

synapsesocial.com/papers/68c23bd7b210217d64786fa5https://doi.org/10.1080/17576180.2025.2554563
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risdiplam in Presymptomatic Spinal Muscular Atrophy2025
  2. 2Longitudinal efficacy of risdiplam treatment in Chinese children with spinal muscular atrophy2025
  3. 3Neurofilaments as Biomarkers of the Efficacy of Risdiplam Treatment in Early SMA Phenotypes Diagnosed by Newborn Screening2025
  4. 4Safety of Risdiplam in Japanese Patients with Spinal Muscular Atrophy: A 12‑Month Interim Analysis of a Postmarketing Surveillance Study2025 · 1 citations
  5. 5Survival motor neuron protein is the optimal biomarker for evaluating the risdiplam treatment2025 · 4 citations